Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. clinic laser medicine
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Books
Magazines
Downloads
Videos

Refine by
Date

  • Older

Clinic Laser Medicine Articles & Analysis

90 news found

The Role of Laser Therapy and Advanced Diagnostics in Modern Clinical Medicine

The Role of Laser Therapy and Advanced Diagnostics in Modern Clinical Medicine

Laser therapy is transforming clinical medicine, offering innovative solutions for skin therapy, cervical surgery, and gynecological procedures. ...

ByContent Management Test Company 89798798


SOPHiA Genetics Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024

SOPHiA Genetics Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an update from the Company’s work with biopharma company Boundless Bio. SOPHiA GENETICS first partnered with Boundless Bio in 2022 to develop and deploy Boundless Bio’s extrachromosomal DNA (ecDNA) detection algorithm as a clinical trial device, to ...

BySOPHiA Genetics


Dreams and Sleep Quality:  Finding the Best Anti-Snoring Device

Dreams and Sleep Quality: Finding the Best Anti-Snoring Device

Are you restless during sleep at night? Do you often wake up at night due to bad dreams or have difficulty in falling asleep? Are you anxious before you sleep? There are a variety of issues that can hamper proper and restful sleep at night, apart from snoring. According to University of Arizona clinical professor of medicine and dream specialist, Rubin Naiman, PhD, the two key components of good ...

ByTannerMedico A/S - Asonor


CY6463 administration is linked to improvements in Alzheimer’s disease-relevant biomarkers, as revealed by eXplainable AI-driven analysis of multiple Phase 1 clinical trials ?

CY6463 administration is linked to improvements in Alzheimer’s disease-relevant biomarkers, as revealed by eXplainable AI-driven analysis of multiple Phase 1 clinical trials ?

Phase 1 studies show improvement in cognitive factors, consistent with therapeutic potential of CY6463 to improve key features in neurological diseases CY6463 favorable tolerability and safety profile was confirmed Ariana Pharma, a leading Artificial Intelligence (AI) drug development company, in collaboration with Cyclerion Therapeutics, presented today safety and pharmacodynamic results ...

ByAriana Pharma


Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors

Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors

Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted PRAC’s recommendation to add measures to minimise risk of serious side effects with JAK inhibitors for chronic inflammatory disorders. “JAK inhibitors are an important treatment option ...

ByGalapagos NV


Regor announces China NMPA approval of the IND for RGT-264 phosphate tablet, a potent and selective HPK1 inhibitor

Regor announces China NMPA approval of the IND for RGT-264 phosphate tablet, a potent and selective HPK1 inhibitor

Regor Therapeutics, a clinical-stage biotech company, announced today the Investigational New Drug (IND) Application for RGT-264 phosphate tablet, a small molecular selective hematopoietic progenitor kinase (HPK1) inhibitor has been approved by the National Medical Products Administration (NMPA) of China. RGT-264 phosphate tablet is a highly potent and selective HPK1 inhibitor. HPK1 kinase ...

ByRegor Pharmaceuticals Inc.


BIOMARK’s GLIOBLASTOMA Study Published in CANCERS Demonstrates Inhibiting SAT1 sensitized cancer cells towards radiation and chemotherapy

BIOMARK’s GLIOBLASTOMA Study Published in CANCERS Demonstrates Inhibiting SAT1 sensitized cancer cells towards radiation and chemotherapy

Vancouver, British Columbia – (October 27th, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today the publication of a preclinical study demonstrating therapeutic capabilities of its SAT1 cancer marker in glioblastoma (GB) ...

ByBioMark Diagnostics Inc.


AI -driven analysis of Parkinson’s Disease Dementia clinical trial reveals potential molecular mechanism of blarcamesine (ANAVEX2-73) in restoring key neurodegenerative pathways

AI -driven analysis of Parkinson’s Disease Dementia clinical trial reveals potential molecular mechanism of blarcamesine (ANAVEX2-73) in restoring key neurodegenerative pathways

Ariana Pharma, the leading Al-driven precision medicine company, has announced the first comprehensive blarcamesine pathway analysis impact using extensive data from the ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia (PDD) clinical study. Initial results were presented by Ariana Pharma at the Alzheimer’s Association International Conference (AAIC 2022) in San Diego, in ...

ByAriana Pharma


Classification of Fractional Lasers

Classification of Fractional Lasers

Fractional laser is a commonly used instrument in clinical beauty medicine. In addition to treating acne scars, burn scars, and trauma scars, it also has a good effect on facial rejuvenation, freckle removal, skin shrinking, and stretch marks. ...

ByBvlaser Bestview Medical and Beauty Equipment Co., Ltd


Updated results from clinical trial with Diamyd presented today at diabetes conference

Updated results from clinical trial with Diamyd presented today at diabetes conference

Updated 12-month results from the open-label investigator-initated Phase II clinical trial GADinLADA that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd® in individuals diagnosed with Latent Autoimmune Diabetes in Adults (LADA) were presented today at the European Association for the Study of Diabetes (EASD) conference in Stockholm, Sweden. The updated ...

ByDiamyd Medical AB


miR Scientific launches "Can do Blue" on September 1, 2022, as Prostate Cancer Awareness Month

miR Scientific launches "Can do Blue" on September 1, 2022, as Prostate Cancer Awareness Month

NEW YORK and SAN JUAN, Puerto Rico, Aug. 18, 2022 /PRNewswire/ -- miR Scientific, LLC announced the launch of national event #CanDoBlue to create awareness of the need for widespread prostate cancer testing during the 2022 Prostate Cancer Awareness Month (also known as "PCAM"). On September 1, New York, New Jersey, Chicago, and Puerto Rico will simultaneously light up dozens of landmarks and ...

BymiR Scientific, LLC


Five-month results from Diamyd trial in LADA published in peer-reviewed scientific journal

Five-month results from Diamyd trial in LADA published in peer-reviewed scientific journal

An article presenting the 5-month interim results from the open-label trial GADinLADA that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd®, has been published in the peer-reviewed scientific journal Frontiers in Endocrinology. As communicated on December 7, 2021, immunological analyses after 5-months showed that the treatment with Diamyd® induced a ...

ByDiamyd Medical AB


Positive Clinical Results for Bluejay’s Symphony IL-6 Test Presented at AACC 2022

Positive Clinical Results for Bluejay’s Symphony IL-6 Test Presented at AACC 2022

Demonstrated 98% NPV1 to Identify COVID-19 Patients at Risk for Severe Illness Study Data Indicate Symphony IL-6 Test Could be a Rapid and Precise Diagnostic Platform for Near-Patient Management of Critical Care Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on developing cost-effective, rapid, ...

ByBluejay Diagnostics, Inc.


Ariana Pharma strengthens management team with appointments of VP Business Development and Chief Financial Officer

Ariana Pharma strengthens management team with appointments of VP Business Development and Chief Financial Officer

Ariana Pharma, the leading eXplainable Artificial Intelligence (xAI) drug development company, announce the appointments of Dr. Marion Soto as Vice President, Business Development and Bertrand Lellouche as Chief Financial Officer. The financial and commercial experience of Marion and Bertrand will further drive Ariana’s accelerated growth. Marion and Bertrand will be bringing their ...

ByAriana Pharma


Todd C. Villines, M.D. Joins Elucid as new Chief Medical Officer

Todd C. Villines, M.D. Joins Elucid as new Chief Medical Officer

BOSTON – July 26, 2022 – Elucid, a novel non-invasive software company providing physicians with AI-powered imaging to characterize cardiovascular disease, is pleased to announce that Todd C. Villines, MD, is joining the company as Chief Medical Officer. Dr. Villines will be leading clinical strategy development and execution for Elucid’s commercial and in-development ...

ByElucid


TeraRecon Announces DocPanel Signs Contract for Intuition Titanium, Reaffirming its Cardiothoracic Imaging Service Commitment

TeraRecon Announces DocPanel Signs Contract for Intuition Titanium, Reaffirming its Cardiothoracic Imaging Service Commitment

TeraRecon, a ConcertAI company and a leader in advanced medical visualization using AI to improve patient care, today announced U.S.-based DocPanel, the world’s first radiology marketplace offering access to over 500 fellowship trained radiologists available for radiological reads, second opinions, and educational consults, has signed a contract for TeraRecon’s advanced visualization ...

ByTeraRecon, Inc.


Promising topline results for intralymphatic Diamyd in patients with LADA

Promising topline results for intralymphatic Diamyd in patients with LADA

The primary endpoints of safety and tolerability were met in the open-label investigator-initiated Phase II clinical trial GADinLADA, in which the diabetes vaccine Diamyd® was administered directly into the lymph node of 14 patients aged 30 to 70 years with the autoimmune form of diabetes called LADA (Latent Autoimmune Diabetes in Adults). Analyses also showed a positive immunological ...

ByDiamyd Medical AB


Ariana Pharma, OmiCure and Centre Léon Bérard (CLB) Comprehensive Cancer Center announce strategic collaboration to implement AI-driven Precision Medicine for cancer patients.

Ariana Pharma, OmiCure and Centre Léon Bérard (CLB) Comprehensive Cancer Center announce strategic collaboration to implement AI-driven Precision Medicine for cancer patients.

Ariana Pharma and OmiCure announce their collaboration with the renowned CLB Cancer Center to apply OmiCure and Ariana Artificial Intelligence (AI) capabilities to find more efficient treatments for cancer patients. The data were communicated at ASCO 2022 last week and showed that Artificial Intelligence RNA-based therapeutic recommendations have the potential to expand personalized cancer ...

ByAriana Pharma


EsoCap holds a multidisciplinary advisory board meeting on Barrett’s esophagus

EsoCap holds a multidisciplinary advisory board meeting on Barrett’s esophagus

EsoCap AG organized a multidisciplinary scientific advisory board meeting with eight international experts in Barrett’s esophagus (BE) in Zurich EsoCap’s technology for the topical treatment of Barrett’s esophagus was recognized by the experts for having high potential for clinical success EsoCap’s proprietary and unique targeted application technology for the upper ...

ByEsoCap AG


3DBio Therapeutics and the Microtia-Congenital Ear Deformity Institute Conduct Human Ear Reconstruction Using 3D-Bioprinted Living Tissue Implant in a First-in-Human Clinical Trial

3DBio Therapeutics and the Microtia-Congenital Ear Deformity Institute Conduct Human Ear Reconstruction Using 3D-Bioprinted Living Tissue Implant in a First-in-Human Clinical Trial

3DBio Therapeutics (3DBio), a clinical-stage regenerative medicine company, and the Microtia-Congenital Ear Deformity Institute announced they have conducted a human ear reconstruction using the AuriNovo™ implant, an investigational, patient-matched, 3D-bioprinted living tissue ear implant. The groundbreaking reconstructive procedure in the first-in-human Phase 1/2a clinical trial is ...

By3DBio Therapeutics

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT